Get started
Author

Niklas Landberg

Observed names: Landberg, Niklas, N Landberg
ORCID: 0000-0001-6752-6507
Observed ORCID: 0000-0001-6752-6507
OpenAlex ID: A5081722419
IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
2016 · Helena Ågerstam, Nils Hansen, et al. · Blood · 101
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
2022 · Daniel Thomas, Manhong Wu, et al. · Cancer Discovery · 75
PDF
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
2017 · Niklas Landberg, Sofia von Palffy, et al. · Haematologica · 73
PDF
Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2023 · Miles H. Linde, Amy C. Fan, et al. · Cancer Discovery · 65
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome
2015 · N Landberg, N Hansen, et al. · Leukemia · 54
PDF
Clonal competition within complex evolutionary hierarchies shapes AML over time
2020 · Carl Sandén, Henrik Lilljebjörn, et al. · Nature Communications · 31
PDF
Primary cells in BCR/FGFR1‐positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib
2017 · Niklas Landberg, Arta Dreimane, et al. · European Journal Of Haematology · 25
IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation
2023 · Niklas Landberg, Thomas Köhnke, et al. · Blood Cancer Discovery · 23
Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR‐ABL1 , a Swedish population‐based study
2021 · Christina Orsmark‐Pietras, Niklas Landberg, et al. · Genes Chromosomes and Cancer · 19
PDF
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells
2014 · M Askmyr, H Ågerstam, et al. · Blood Cancer Journal · 17
PDF
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function
2012 · N Hansen, H Ågerstam, et al. · Leukemia · 17
PDF
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
2019 · Sofia von Palffy, Niklas Landberg, et al. · Haematologica · 12
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
2022 · Sofia von Palffy, Hanna Thorsson, et al. · Blood Advances · 9
PDF
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes
2025 · Henrik Lilljebjörn, Pablo Peña-Martínez, et al. · Nature Communications · 7
PDF
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia
2025 · Carl Sandén, Niklas Landberg, et al. · Nature Cancer · 7
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells
2017 · Maria Askmyr, Sofia von Palffy, et al. · PLoS ONE · 4
PDF
Supplementary Figures from Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
2023 · Daniel Thomas, Manhong Wu, et al. · 2
PDF
Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML
2022 · Niklas Landberg, Thomas Koehnke, et al. · Blood · 2
The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy
2025 · Sarah Bertoli, Niklas Landberg, et al. · Blood · 1
Supplementary Figures 1-6 from IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation
2024 · Niklas Landberg, Thomas Köhnke, et al. · 1
Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia
2023 · Jesse W. Tai, Guan Li, et al. · Blood · 1
Modeling Chronic Myeloid Leukemia in Immunodeficient Mice Reveals an Inflammatory State with Expansion of Aberrant Mast Cells and Accumulation of Pre B Cells
2014 · Maria Askmyr, Helena Agerstam, et al. · Blood · 1
Distinct clinical and molecular profiles of acute myeloid leukemia defined by mutations in IDH1, IDH2, and TET2
2026 · Fanny Asbaghi, Erik Håkansson, et al. · Haematologica
PDF
Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML
2026 · Matilda Arvidsson Kvissberg, Christer Nilsson, et al. · Annals of Hematology
PDF
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia
2026 · Sarah Bertoli, Niklas Landberg, et al. · Blood
Works count: 100
Citation count: 547
H-index: 12
I10-index: 12
Year
Topic
Type